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comes from BOT (insulin glargine plus glimepiride and met-
formine) in comparison to a conventional therapy (CT) with pre-
mixed insulin (30/70) twice daily were analysed. METHODS:
The applied DMM is an epidemiological simulation model devel-
oped to predict the progression of the disease in a simulated dia-
betes patient population. Baseline values for the simulations:
mean age of the population 60 ± 9.0 years, mean duration of
diabetes 9.0 ± 7.0 years and mean HbA1c value 8.8 ± 0.9%. The
response rate for BOT (HbA1c ≤ 7%) was 49% and for CT
39%. Mean HbA1c for responders were 6.46% and 6.55%
respectively, whereas values for non-responders were assumed 
to be 7.82% and 8.09%. The responder rates in the sensitivity
analyses were varied in 2%-steps, with a range between 44%
and 56%. Additionally the impact of age/duration variations was
analysed. RESULTS: The relative risk reduction (RRR) for micro
vascular events after 10 simulation years for BOT versus CT
cohort varied between 14% (ESRD) and 2% (retinopathy). The
sensitivity analysis showed that also with a worst-case scenario
(i.e. BOT responder-rate of 44%) the RRR for ESRD was still
in the range of 10%. Patient stratiﬁcation on age and duration
demonstrated that the response-rates had the strongest inﬂuence
on diabetes complications of kidneys and nerve system, espe-
cially in the earlier stages of diabetes. CONCLUSIONS: Better
HbA1c control with BOT compared to CT is estimated to reduce
long-term micro-vascular complications based on simulations
with the DMM.
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OBJECTIVES: The purpose of this study was to measure the rel-
ative outcome of treatment following initiation of treatment with
insulin glargine versus insulin detemir in General Practice in
people with both type 1 (T1DM) and type 2 (T2DM) diabetes
mellitus. METHODS: Data were extracted from a proprietary
database of primary care records (THIN). Cases were selected if
treated exclusively with either glargine or detemir. Glycaemic
control (HbA1c) was extracted for up to nine months following
basal analog initiation and averaged over three quarterly periods,
given the recent launch of detemir. Records of GP contacts for
hypoglycaemia were also examined. RESULTS: There were 4844
subjects available for analysis in the glargine group and 528 sub-
jects in the detemir group; baseline cohort characteristics were
equivalent. In T1DM the glargine and detemir groups compared
respectively: 40.8 years vs. 39.2 years old, 12.5 years vs. 12.2
years diabetes duration, 47.9% female vs. 42.9% female and
26.4 kg/m2 BMI vs. 26.9 kg/m2. In T2DM the glargine and
detemir groups respectively: 61.4 years vs. 58.6 years old, 10.3
years vs. 9.0 years diabetes duration, 46.0% female vs. 45.9%
female, 30.2 kg/m2 BMI vs. 31.0 kg/m2. The HbA1c deterioration
proﬁle was very similar prior to switching to either treatment.
Following switching, diabetes control was superior in T1DM
when treated with glargine; the mean reduction in HbA1c using
glargine compared to baseline was 0.19%, 0.36%, and 0.37%
for Q1 to Q3, respectively (p < 0.01). A similar pattern was
evident in T2DM, where the improvement was 0.52%, 0.82%,
and 0.89%, respectively (p < 0.001). There were fewer reports
of GP-treated hypoglycaemia episodes with glargine vs. detemir
(4.80 per 100 patient years [PHPY] vs. 6.40 PHPY; p < 0.05).
CONCLUSIONS: When used in general practice, glargine
resulted in superior glycaemic control and fewer hypoglycaemic
episodes than detemir in both Type 1 and Type 2 diabetes.
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OBJECTIVES: The Kerraboot is a non-pressurized boot-like
dressing designed to provide an environment for improved
healing without the need for conventional dressings and which
can be more readily replaced by the healthcare professional or
patient. The cost beneﬁt of this product compared to conven-
tional dressing management was investigated. METHODS:
A cost model based on published costs for conventional 
dressing treatment was developed and the costs of conventional
dressings versus the Kerraboot compared for different grades of
diabetic foot ulcers, excluding those that require surgical re-
vascularization. Sensitivity analyses were performed for different
treatment regimens, reduced nursing requirements as a result of
increased patient self-dressing, use of longer intervals between
dressing changes, differing dressing types and dressing costs.
RESULTS: Use of the Kerraboot compared to conventional
dressings saves nursing time resulting in a reduction in nursing
costs of 29–78% per dressing change. Use of the Kerraboot
results in overall labour cost savings per patient of −181% (£516
v £184 – Ulcer grade; Level 1), 15% (£990 v £1139 – Level 2),
and 48% (£3805 v £7300 – Level 3) compared to standard con-
ventional dressing. Assessment of Kerraboot use across all levels
weighted by severity incidence results in labour cost savings.
Patient beneﬁts such as convenience and improved social accep-
tance have not been costed. CONCLUSIONS: Modelling the
variable labour costs of treating diabetic foot ulcers with the
Kerraboot verses conventional dressings demonstrates that
overall costs will be reduced with the Kerraboot. The greatest
saving is seen with level 3 ulcer management. Indirect costs
provide further savings. 
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative ﬁnancial costs associated with the use of insulin glargine
versus insulin detemir in routine primary care clinical practice in
the UK using real-life, observational data. METHODS: Pre-
scription data was extracted from a proprietary primary care
data source, The Health Improvement Network (THIN). Basal
analogue-naïve patients with at least six months prior history
were selected if initiated on either glargine or detemir exclusively
in the study period. All diabetes-related prescriptions, between
and including the ﬁrst and last recorded prescription dates for
glargine or detemir were analysed. These dates deﬁned the
known exposure to either insulin. Medical diagnoses analysis
classiﬁed cases as having either Type 1 or Type 2 diabetes mel-
